Skip to content
Screener

Emergent Biosolutions EBS All other revenue — Total revenues

Other product segments

MCM Product sales
$168M+188%
Commercial Product sales
$52.4M-22.4%

Similar metrics at other companies

FTAI Aviation Ltd. logo
FTAIOther revenue — Total revenues
$6.21M+19,923%
Kinetik Holdings logo
KNTKOther revenue — Total revenues
$3.97M+40.2%
Asset Entities logo
ASSTOther revenue — Total revenues
$41K+78.3%
FIP
FIPOther revenue — Total revenues
$1.49M+434%
Red Robin Gourmet Burgers logo
RRGBOther revenue — Total revenues
$2.23M+8.5%
Agilon Health logo
AGLOther operating revenue — Total revenues
$1.82M-38.1%

Other financials

Income statement

See full
Revenue$234.3M+66.3%
Gross profit$137.2M+85.4%
Operating income-$125.1M-7,919%
Net income-$180.2M-1,402%
EPS (diluted)-$3.49-1,486%

Balance sheet

See full
Cash & equivalents$140.9M-48.0%
Total debt$588.2M-13.0%
Total equity$341.4M-36.3%
Total assets$1.1B-21.2%

Cash flow

See full
Operating cash flow$56.1M-47.3%
CapEx$2.1M-27.6%
Free cash flow$54.0M-47.8%

Valuation

See full
Market cap$248.16M-43.0%
Enterprise value$695.46M-17.3%
P/S0.3×-0.2×

Profitability

See full
Gross margin55.9%+2.4pp
Operating margin15%+10.3pp
Net margin9.6%+5.8pp
FCF margin11.9%

Returns & leverage

See full
Return on equity13.9%+8.1pp
Debt / equity1.7×+0.5×
Current ratio5.4×-0.2×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Emergent Biosolutions’s 10-Q, filed August 6, 2026.

Filed
Aug 5, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001367644-26-000082
Line itemThree Months Ended June 30, 2026 / USGThree Months Ended June 30, 2026 / Non-USGThree Months Ended June 30, 2026 / TotalThree Months Ended June 30, 2025 / USGThree Months Ended June 30, 2025 / Non-USGThree Months Ended June 30, 2025 / Total
Commercial Product sales$1.0$51.4$52.4$1.2$66.3$67.5
MCM Product sales148.619.4168.046.012.458.4
All other revenues (1)7.56.413.910.64.415.0
Total revenues$157.1$77.2$234.3$57.8$83.1$140.9
(1) “All other revenues” includes Services and Contracts and grants revenue.

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Emergent Biosolutions's all other revenue — total revenues?
Emergent Biosolutions (EBS) reported all other revenue — total revenues of $13.9M in Q2 2026.
How has Emergent Biosolutions's all other revenue — total revenues changed year-over-year?
Emergent Biosolutions's all other revenue — total revenues decreased by 7.3% year-over-year, from $15M to $13.9M.
What is the long-term trend for Emergent Biosolutions's all other revenue — total revenues?
Over 2 years (2023 to 2025), Emergent Biosolutions's all other revenue — total revenues has grown at a -24.3% compound annual growth rate (CAGR), from $104.8M to $60.1M.
What does all other revenue — total revenues mean?
This metric represents the aggregate revenue generated from business activities or product lines that do not fall under the company's primary reporting segments. It captures secondary revenue streams, such as ancillary services, non-core product sales, or miscellaneous contract work, providing insight into the diversification of the company's income base. Monitoring this figure helps investors understand the contribution of peripheral operations to the overall financial performance of the organization.

Ask your AI about Emergent Biosolutions's all other revenue — total revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude